5:05 PM ET
8-K
Other 8-K Filing
Quoin Pharmaceuticals Other 8-K Filing
Shareholders of Quoin Pharmaceuticals approved a proposal to amend beneficial ownership limitations for investors from previous private placements. The amendment allows investors to increase their ownership cap from 4.99% to up to 9.99% of outstanding ordinary shares upon written notice. This change applies to transactions consummated in October 2025 and August 2026 and aligns with both US and Israeli securities laws.